載入...
Initial treatment for patients with chronic myeloid leukemia
The first-line treatment of chronic myeloid leukemia is based on the three currently available tyrosine kinase inhibitors (TKIs), namely imatinib, nilotinib and dasatinib. Nilotinib and dasatinib are more potent, and it is predicted that, in comparison with imatinib, they can reduce the risk of prog...
Na minha lista:
| 發表在: | Leukemia Suppl |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group
2012
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4851202/ https://ncbi.nlm.nih.gov/pubmed/27175245 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leusup.2012.21 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|